The FDA assessed the safety and performance of atidarsagene autotemcel based upon facts from 37 little ones who acquired atidarsagene autotemcel in two single-arm, open-label clinical trials As well as in an expanded accessibility program.[seven] Young children who obtained procedure with atidarsagene autotemcel ended up when compared with untreate